nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—ABCB1—melanoma	0.271	1	CbGaD
Eletriptan—CYP3A4—Temozolomide—melanoma	0.0668	0.284	CbGbCtD
Eletriptan—CYP2D6—Vemurafenib—melanoma	0.0576	0.245	CbGbCtD
Eletriptan—ABCB1—Dactinomycin—melanoma	0.0406	0.173	CbGbCtD
Eletriptan—CYP3A4—Vemurafenib—melanoma	0.0366	0.156	CbGbCtD
Eletriptan—HTR1D—meninx—melanoma	0.0223	0.443	CbGeAlD
Eletriptan—ABCB1—Docetaxel—melanoma	0.021	0.0892	CbGbCtD
Eletriptan—CYP3A4—Docetaxel—melanoma	0.0126	0.0534	CbGbCtD
Eletriptan—HTR1B—blood vessel—melanoma	0.00261	0.0519	CbGeAlD
Eletriptan—HTR1D—blood vessel—melanoma	0.00253	0.0502	CbGeAlD
Eletriptan—HTR7—endothelium—melanoma	0.00219	0.0434	CbGeAlD
Eletriptan—HTR7—blood vessel—melanoma	0.00202	0.04	CbGeAlD
Eletriptan—HTR1F—head—melanoma	0.00193	0.0383	CbGeAlD
Eletriptan—HTR1E—head—melanoma	0.00167	0.0331	CbGeAlD
Eletriptan—PTGS1—endothelium—melanoma	0.00151	0.03	CbGeAlD
Eletriptan—HTR7—neck—melanoma	0.00144	0.0286	CbGeAlD
Eletriptan—PTGS1—blood vessel—melanoma	0.00139	0.0277	CbGeAlD
Eletriptan—HTR1D—eye—melanoma	0.00135	0.0267	CbGeAlD
Eletriptan—HTR2B—skin of body—melanoma	0.00109	0.0216	CbGeAlD
Eletriptan—ABCB1—blood vessel—melanoma	0.000824	0.0164	CbGeAlD
Eletriptan—HTR1B—head—melanoma	0.00079	0.0157	CbGeAlD
Eletriptan—HTR1D—head—melanoma	0.000764	0.0152	CbGeAlD
Eletriptan—HTR2B—head—melanoma	0.000711	0.0141	CbGeAlD
Eletriptan—Neuropathy peripheral—Temozolomide—melanoma	0.000652	0.00247	CcSEcCtD
Eletriptan—Stomatitis—Temozolomide—melanoma	0.000648	0.00245	CcSEcCtD
Eletriptan—PTGS1—skin of body—melanoma	0.000645	0.0128	CbGeAlD
Eletriptan—HTR1A—head—melanoma	0.000637	0.0127	CbGeAlD
Eletriptan—Chills—Bleomycin—melanoma	0.000635	0.0024	CcSEcCtD
Eletriptan—Alopecia—Bleomycin—melanoma	0.000625	0.00237	CcSEcCtD
Eletriptan—Sinusitis—Temozolomide—melanoma	0.000624	0.00236	CcSEcCtD
Eletriptan—Hallucination—Carmustine—melanoma	0.000615	0.00232	CcSEcCtD
Eletriptan—Hypoaesthesia—Carmustine—melanoma	0.000615	0.00232	CcSEcCtD
Eletriptan—Flushing—Dactinomycin—melanoma	0.000613	0.00232	CcSEcCtD
Eletriptan—Hypersensitivity—Vemurafenib—melanoma	0.000612	0.00231	CcSEcCtD
Eletriptan—HTR7—head—melanoma	0.000609	0.0121	CbGeAlD
Eletriptan—Oedema peripheral—Carmustine—melanoma	0.000609	0.0023	CcSEcCtD
Eletriptan—Atrial fibrillation—Docetaxel—melanoma	0.000606	0.00229	CcSEcCtD
Eletriptan—Asthenia—Vemurafenib—melanoma	0.000596	0.00225	CcSEcCtD
Eletriptan—Visual impairment—Carmustine—melanoma	0.000595	0.00225	CcSEcCtD
Eletriptan—Hypoaesthesia—Temozolomide—melanoma	0.000594	0.00225	CcSEcCtD
Eletriptan—Hallucination—Temozolomide—melanoma	0.000594	0.00225	CcSEcCtD
Eletriptan—Pharyngitis—Temozolomide—melanoma	0.000593	0.00224	CcSEcCtD
Eletriptan—Chills—Dactinomycin—melanoma	0.000592	0.00224	CcSEcCtD
Eletriptan—Urinary tract disorder—Temozolomide—melanoma	0.00059	0.00223	CcSEcCtD
Eletriptan—PTGS1—mammalian vulva—melanoma	0.000588	0.0117	CbGeAlD
Eletriptan—Oedema peripheral—Temozolomide—melanoma	0.000588	0.00222	CcSEcCtD
Eletriptan—Pruritus—Vemurafenib—melanoma	0.000587	0.00222	CcSEcCtD
Eletriptan—Urethral disorder—Temozolomide—melanoma	0.000585	0.00221	CcSEcCtD
Eletriptan—Alopecia—Dactinomycin—melanoma	0.000583	0.00221	CcSEcCtD
Eletriptan—Visual impairment—Temozolomide—melanoma	0.000575	0.00218	CcSEcCtD
Eletriptan—Flushing—Carmustine—melanoma	0.000573	0.00217	CcSEcCtD
Eletriptan—Ill-defined disorder—Bleomycin—melanoma	0.000572	0.00216	CcSEcCtD
Eletriptan—Anaemia—Bleomycin—melanoma	0.00057	0.00215	CcSEcCtD
Eletriptan—Diarrhoea—Vemurafenib—melanoma	0.000568	0.00215	CcSEcCtD
Eletriptan—Migraine—Docetaxel—melanoma	0.000565	0.00214	CcSEcCtD
Eletriptan—Tinnitus—Temozolomide—melanoma	0.000557	0.00211	CcSEcCtD
Eletriptan—Malaise—Bleomycin—melanoma	0.000556	0.0021	CcSEcCtD
Eletriptan—Flushing—Temozolomide—melanoma	0.000554	0.0021	CcSEcCtD
Eletriptan—Arrhythmia—Carmustine—melanoma	0.000552	0.00209	CcSEcCtD
Eletriptan—Leukopenia—Bleomycin—melanoma	0.000552	0.00209	CcSEcCtD
Eletriptan—Dizziness—Vemurafenib—melanoma	0.000549	0.00208	CcSEcCtD
Eletriptan—Alopecia—Carmustine—melanoma	0.000546	0.00206	CcSEcCtD
Eletriptan—Ataxia—Docetaxel—melanoma	0.00054	0.00204	CcSEcCtD
Eletriptan—Immune system disorder—Temozolomide—melanoma	0.000539	0.00204	CcSEcCtD
Eletriptan—Cough—Bleomycin—melanoma	0.000538	0.00203	CcSEcCtD
Eletriptan—Chills—Temozolomide—melanoma	0.000536	0.00203	CcSEcCtD
Eletriptan—Ill-defined disorder—Dactinomycin—melanoma	0.000533	0.00202	CcSEcCtD
Eletriptan—Anaemia—Dactinomycin—melanoma	0.000531	0.00201	CcSEcCtD
Eletriptan—Liver function test abnormal—Docetaxel—melanoma	0.00053	0.002	CcSEcCtD
Eletriptan—Vomiting—Vemurafenib—melanoma	0.000528	0.002	CcSEcCtD
Eletriptan—Alopecia—Temozolomide—melanoma	0.000528	0.002	CcSEcCtD
Eletriptan—Dry skin—Docetaxel—melanoma	0.000526	0.00199	CcSEcCtD
Eletriptan—Myalgia—Bleomycin—melanoma	0.000525	0.00198	CcSEcCtD
Eletriptan—Abdominal pain upper—Docetaxel—melanoma	0.000524	0.00198	CcSEcCtD
Eletriptan—Rash—Vemurafenib—melanoma	0.000523	0.00198	CcSEcCtD
Eletriptan—Dermatitis—Vemurafenib—melanoma	0.000523	0.00198	CcSEcCtD
Eletriptan—Back pain—Carmustine—melanoma	0.00052	0.00197	CcSEcCtD
Eletriptan—Headache—Vemurafenib—melanoma	0.00052	0.00197	CcSEcCtD
Eletriptan—Discomfort—Bleomycin—melanoma	0.000518	0.00196	CcSEcCtD
Eletriptan—Malaise—Dactinomycin—melanoma	0.000518	0.00196	CcSEcCtD
Eletriptan—Cramp muscle—Docetaxel—melanoma	0.000517	0.00195	CcSEcCtD
Eletriptan—Leukopenia—Dactinomycin—melanoma	0.000514	0.00195	CcSEcCtD
Eletriptan—Dysgeusia—Temozolomide—melanoma	0.000509	0.00192	CcSEcCtD
Eletriptan—Confusional state—Bleomycin—melanoma	0.000507	0.00192	CcSEcCtD
Eletriptan—Tremor—Carmustine—melanoma	0.000504	0.00191	CcSEcCtD
Eletriptan—Oedema—Bleomycin—melanoma	0.000503	0.0019	CcSEcCtD
Eletriptan—Back pain—Temozolomide—melanoma	0.000503	0.0019	CcSEcCtD
Eletriptan—HTR2B—lymph node—melanoma	0.000498	0.00989	CbGeAlD
Eletriptan—Anaemia—Carmustine—melanoma	0.000497	0.00188	CcSEcCtD
Eletriptan—Dysphagia—Docetaxel—melanoma	0.000496	0.00188	CcSEcCtD
Eletriptan—Agitation—Carmustine—melanoma	0.000494	0.00187	CcSEcCtD
Eletriptan—Nausea—Vemurafenib—melanoma	0.000493	0.00186	CcSEcCtD
Eletriptan—Myalgia—Dactinomycin—melanoma	0.000489	0.00185	CcSEcCtD
Eletriptan—Tremor—Temozolomide—melanoma	0.000487	0.00184	CcSEcCtD
Eletriptan—Discomfort—Dactinomycin—melanoma	0.000483	0.00183	CcSEcCtD
Eletriptan—Angina pectoris—Docetaxel—melanoma	0.000483	0.00183	CcSEcCtD
Eletriptan—Ill-defined disorder—Temozolomide—melanoma	0.000482	0.00182	CcSEcCtD
Eletriptan—Leukopenia—Carmustine—melanoma	0.000481	0.00182	CcSEcCtD
Eletriptan—Anaemia—Temozolomide—melanoma	0.00048	0.00182	CcSEcCtD
Eletriptan—Anorexia—Bleomycin—melanoma	0.000479	0.00181	CcSEcCtD
Eletriptan—Agitation—Temozolomide—melanoma	0.000478	0.00181	CcSEcCtD
Eletriptan—Angioedema—Temozolomide—melanoma	0.000475	0.0018	CcSEcCtD
Eletriptan—Hypotension—Bleomycin—melanoma	0.00047	0.00178	CcSEcCtD
Eletriptan—Oedema—Dactinomycin—melanoma	0.000469	0.00177	CcSEcCtD
Eletriptan—Malaise—Temozolomide—melanoma	0.000469	0.00177	CcSEcCtD
Eletriptan—Vertigo—Temozolomide—melanoma	0.000467	0.00177	CcSEcCtD
Eletriptan—Convulsion—Carmustine—melanoma	0.000466	0.00176	CcSEcCtD
Eletriptan—Leukopenia—Temozolomide—melanoma	0.000465	0.00176	CcSEcCtD
Eletriptan—Hypertension—Carmustine—melanoma	0.000464	0.00176	CcSEcCtD
Eletriptan—Palpitations—Temozolomide—melanoma	0.000459	0.00174	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Bleomycin—melanoma	0.000458	0.00173	CcSEcCtD
Eletriptan—Myalgia—Carmustine—melanoma	0.000458	0.00173	CcSEcCtD
Eletriptan—Anxiety—Carmustine—melanoma	0.000456	0.00173	CcSEcCtD
Eletriptan—Cough—Temozolomide—melanoma	0.000454	0.00172	CcSEcCtD
Eletriptan—Paraesthesia—Bleomycin—melanoma	0.000452	0.00171	CcSEcCtD
Eletriptan—Weight increased—Docetaxel—melanoma	0.000451	0.00171	CcSEcCtD
Eletriptan—Convulsion—Temozolomide—melanoma	0.00045	0.0017	CcSEcCtD
Eletriptan—Weight decreased—Docetaxel—melanoma	0.000449	0.0017	CcSEcCtD
Eletriptan—Hypertension—Temozolomide—melanoma	0.000449	0.0017	CcSEcCtD
Eletriptan—Dyspnoea—Bleomycin—melanoma	0.000448	0.0017	CcSEcCtD
Eletriptan—Anorexia—Dactinomycin—melanoma	0.000447	0.00169	CcSEcCtD
Eletriptan—Confusional state—Carmustine—melanoma	0.000443	0.00167	CcSEcCtD
Eletriptan—Arthralgia—Temozolomide—melanoma	0.000443	0.00167	CcSEcCtD
Eletriptan—Myalgia—Temozolomide—melanoma	0.000443	0.00167	CcSEcCtD
Eletriptan—Anxiety—Temozolomide—melanoma	0.000441	0.00167	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000439	0.00166	CcSEcCtD
Eletriptan—Oedema—Carmustine—melanoma	0.000439	0.00166	CcSEcCtD
Eletriptan—Discomfort—Temozolomide—melanoma	0.000437	0.00165	CcSEcCtD
Eletriptan—Decreased appetite—Bleomycin—melanoma	0.000437	0.00165	CcSEcCtD
Eletriptan—Acute coronary syndrome—Docetaxel—melanoma	0.000436	0.00165	CcSEcCtD
Eletriptan—ABCB1—retina—melanoma	0.000434	0.00863	CbGeAlD
Eletriptan—Myocardial infarction—Docetaxel—melanoma	0.000434	0.00164	CcSEcCtD
Eletriptan—Neuropathy peripheral—Docetaxel—melanoma	0.000434	0.00164	CcSEcCtD
Eletriptan—Dry mouth—Temozolomide—melanoma	0.000433	0.00164	CcSEcCtD
Eletriptan—Stomatitis—Docetaxel—melanoma	0.000431	0.00163	CcSEcCtD
Eletriptan—Pain—Bleomycin—melanoma	0.00043	0.00163	CcSEcCtD
Eletriptan—Conjunctivitis—Docetaxel—melanoma	0.00043	0.00163	CcSEcCtD
Eletriptan—Tachycardia—Carmustine—melanoma	0.000428	0.00162	CcSEcCtD
Eletriptan—Confusional state—Temozolomide—melanoma	0.000428	0.00162	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000427	0.00162	CcSEcCtD
Eletriptan—Oedema—Temozolomide—melanoma	0.000424	0.0016	CcSEcCtD
Eletriptan—PTGS1—head—melanoma	0.000421	0.00836	CbGeAlD
Eletriptan—Anorexia—Carmustine—melanoma	0.000418	0.00158	CcSEcCtD
Eletriptan—Epistaxis—Docetaxel—melanoma	0.000417	0.00158	CcSEcCtD
Eletriptan—Nervous system disorder—Temozolomide—melanoma	0.000416	0.00157	CcSEcCtD
Eletriptan—Feeling abnormal—Bleomycin—melanoma	0.000414	0.00157	CcSEcCtD
Eletriptan—Skin disorder—Temozolomide—melanoma	0.000412	0.00156	CcSEcCtD
Eletriptan—Hypotension—Carmustine—melanoma	0.00041	0.00155	CcSEcCtD
Eletriptan—Hyperhidrosis—Temozolomide—melanoma	0.00041	0.00155	CcSEcCtD
Eletriptan—Decreased appetite—Dactinomycin—melanoma	0.000408	0.00154	CcSEcCtD
Eletriptan—Fatigue—Dactinomycin—melanoma	0.000404	0.00153	CcSEcCtD
Eletriptan—Anorexia—Temozolomide—melanoma	0.000404	0.00153	CcSEcCtD
Eletriptan—Pain—Dactinomycin—melanoma	0.000401	0.00152	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Carmustine—melanoma	0.0004	0.00151	CcSEcCtD
Eletriptan—Urticaria—Bleomycin—melanoma	0.0004	0.00151	CcSEcCtD
Eletriptan—Rhinitis—Docetaxel—melanoma	0.000398	0.00151	CcSEcCtD
Eletriptan—Body temperature increased—Bleomycin—melanoma	0.000398	0.0015	CcSEcCtD
Eletriptan—Insomnia—Carmustine—melanoma	0.000397	0.0015	CcSEcCtD
Eletriptan—Hypoaesthesia—Docetaxel—melanoma	0.000395	0.00149	CcSEcCtD
Eletriptan—Paraesthesia—Carmustine—melanoma	0.000394	0.00149	CcSEcCtD
Eletriptan—Pharyngitis—Docetaxel—melanoma	0.000394	0.00149	CcSEcCtD
Eletriptan—Urinary tract disorder—Docetaxel—melanoma	0.000392	0.00148	CcSEcCtD
Eletriptan—Dyspnoea—Carmustine—melanoma	0.000391	0.00148	CcSEcCtD
Eletriptan—Oedema peripheral—Docetaxel—melanoma	0.000391	0.00148	CcSEcCtD
Eletriptan—Somnolence—Carmustine—melanoma	0.00039	0.00148	CcSEcCtD
Eletriptan—Urethral disorder—Docetaxel—melanoma	0.000389	0.00147	CcSEcCtD
Eletriptan—Feeling abnormal—Dactinomycin—melanoma	0.000386	0.00146	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Temozolomide—melanoma	0.000386	0.00146	CcSEcCtD
Eletriptan—Insomnia—Temozolomide—melanoma	0.000384	0.00145	CcSEcCtD
Eletriptan—Gastrointestinal pain—Dactinomycin—melanoma	0.000384	0.00145	CcSEcCtD
Eletriptan—Visual impairment—Docetaxel—melanoma	0.000383	0.00145	CcSEcCtD
Eletriptan—Decreased appetite—Carmustine—melanoma	0.000382	0.00144	CcSEcCtD
Eletriptan—Paraesthesia—Temozolomide—melanoma	0.000381	0.00144	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Carmustine—melanoma	0.000379	0.00143	CcSEcCtD
Eletriptan—Dyspnoea—Temozolomide—melanoma	0.000378	0.00143	CcSEcCtD
Eletriptan—Somnolence—Temozolomide—melanoma	0.000377	0.00143	CcSEcCtD
Eletriptan—Pain—Carmustine—melanoma	0.000375	0.00142	CcSEcCtD
Eletriptan—Constipation—Carmustine—melanoma	0.000375	0.00142	CcSEcCtD
Eletriptan—Dyspepsia—Temozolomide—melanoma	0.000373	0.00141	CcSEcCtD
Eletriptan—Body temperature increased—Dactinomycin—melanoma	0.000371	0.0014	CcSEcCtD
Eletriptan—Abdominal pain—Dactinomycin—melanoma	0.000371	0.0014	CcSEcCtD
Eletriptan—Hypersensitivity—Bleomycin—melanoma	0.000371	0.0014	CcSEcCtD
Eletriptan—Decreased appetite—Temozolomide—melanoma	0.000369	0.00139	CcSEcCtD
Eletriptan—Flushing—Docetaxel—melanoma	0.000369	0.00139	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Temozolomide—melanoma	0.000366	0.00138	CcSEcCtD
Eletriptan—Fatigue—Temozolomide—melanoma	0.000366	0.00138	CcSEcCtD
Eletriptan—Constipation—Temozolomide—melanoma	0.000363	0.00137	CcSEcCtD
Eletriptan—Pain—Temozolomide—melanoma	0.000363	0.00137	CcSEcCtD
Eletriptan—Feeling abnormal—Carmustine—melanoma	0.000362	0.00137	CcSEcCtD
Eletriptan—Asthenia—Bleomycin—melanoma	0.000361	0.00136	CcSEcCtD
Eletriptan—Gastrointestinal pain—Carmustine—melanoma	0.000359	0.00136	CcSEcCtD
Eletriptan—Immune system disorder—Docetaxel—melanoma	0.000359	0.00136	CcSEcCtD
Eletriptan—Chills—Docetaxel—melanoma	0.000356	0.00135	CcSEcCtD
Eletriptan—Pruritus—Bleomycin—melanoma	0.000356	0.00135	CcSEcCtD
Eletriptan—Arrhythmia—Docetaxel—melanoma	0.000355	0.00134	CcSEcCtD
Eletriptan—Alopecia—Docetaxel—melanoma	0.000351	0.00133	CcSEcCtD
Eletriptan—Feeling abnormal—Temozolomide—melanoma	0.00035	0.00132	CcSEcCtD
Eletriptan—ABCB1—mammalian vulva—melanoma	0.000348	0.00691	CbGeAlD
Eletriptan—Body temperature increased—Carmustine—melanoma	0.000347	0.00131	CcSEcCtD
Eletriptan—Abdominal pain—Carmustine—melanoma	0.000347	0.00131	CcSEcCtD
Eletriptan—Gastrointestinal pain—Temozolomide—melanoma	0.000347	0.00131	CcSEcCtD
Eletriptan—CYP2D6—head—melanoma	0.000346	0.00687	CbGeAlD
Eletriptan—Hypersensitivity—Dactinomycin—melanoma	0.000346	0.00131	CcSEcCtD
Eletriptan—Dysgeusia—Docetaxel—melanoma	0.000338	0.00128	CcSEcCtD
Eletriptan—Urticaria—Temozolomide—melanoma	0.000337	0.00127	CcSEcCtD
Eletriptan—Asthenia—Dactinomycin—melanoma	0.000337	0.00127	CcSEcCtD
Eletriptan—Abdominal pain—Temozolomide—melanoma	0.000335	0.00127	CcSEcCtD
Eletriptan—Body temperature increased—Temozolomide—melanoma	0.000335	0.00127	CcSEcCtD
Eletriptan—Back pain—Docetaxel—melanoma	0.000334	0.00126	CcSEcCtD
Eletriptan—Muscle spasms—Docetaxel—melanoma	0.000332	0.00126	CcSEcCtD
Eletriptan—Hypersensitivity—Carmustine—melanoma	0.000323	0.00122	CcSEcCtD
Eletriptan—Diarrhoea—Dactinomycin—melanoma	0.000321	0.00121	CcSEcCtD
Eletriptan—Vomiting—Bleomycin—melanoma	0.00032	0.00121	CcSEcCtD
Eletriptan—Anaemia—Docetaxel—melanoma	0.000319	0.00121	CcSEcCtD
Eletriptan—Rash—Bleomycin—melanoma	0.000317	0.0012	CcSEcCtD
Eletriptan—Dermatitis—Bleomycin—melanoma	0.000317	0.0012	CcSEcCtD
Eletriptan—Asthenia—Carmustine—melanoma	0.000315	0.00119	CcSEcCtD
Eletriptan—Hypersensitivity—Temozolomide—melanoma	0.000313	0.00118	CcSEcCtD
Eletriptan—Syncope—Docetaxel—melanoma	0.00031	0.00117	CcSEcCtD
Eletriptan—Leukopenia—Docetaxel—melanoma	0.000309	0.00117	CcSEcCtD
Eletriptan—Palpitations—Docetaxel—melanoma	0.000305	0.00116	CcSEcCtD
Eletriptan—Asthenia—Temozolomide—melanoma	0.000304	0.00115	CcSEcCtD
Eletriptan—Loss of consciousness—Docetaxel—melanoma	0.000304	0.00115	CcSEcCtD
Eletriptan—Cough—Docetaxel—melanoma	0.000302	0.00114	CcSEcCtD
Eletriptan—Diarrhoea—Carmustine—melanoma	0.0003	0.00114	CcSEcCtD
Eletriptan—Pruritus—Temozolomide—melanoma	0.0003	0.00113	CcSEcCtD
Eletriptan—Convulsion—Docetaxel—melanoma	0.000299	0.00113	CcSEcCtD
Eletriptan—Nausea—Bleomycin—melanoma	0.000299	0.00113	CcSEcCtD
Eletriptan—Hypertension—Docetaxel—melanoma	0.000298	0.00113	CcSEcCtD
Eletriptan—Vomiting—Dactinomycin—melanoma	0.000298	0.00113	CcSEcCtD
Eletriptan—Rash—Dactinomycin—melanoma	0.000296	0.00112	CcSEcCtD
Eletriptan—PTGS1—lymph node—melanoma	0.000295	0.00585	CbGeAlD
Eletriptan—Myalgia—Docetaxel—melanoma	0.000294	0.00111	CcSEcCtD
Eletriptan—Arthralgia—Docetaxel—melanoma	0.000294	0.00111	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000292	0.00111	CcSEcCtD
Eletriptan—Dizziness—Carmustine—melanoma	0.00029	0.0011	CcSEcCtD
Eletriptan—Diarrhoea—Temozolomide—melanoma	0.00029	0.0011	CcSEcCtD
Eletriptan—Dry mouth—Docetaxel—melanoma	0.000288	0.00109	CcSEcCtD
Eletriptan—Confusional state—Docetaxel—melanoma	0.000284	0.00108	CcSEcCtD
Eletriptan—Oedema—Docetaxel—melanoma	0.000282	0.00107	CcSEcCtD
Eletriptan—Dizziness—Temozolomide—melanoma	0.000281	0.00106	CcSEcCtD
Eletriptan—Vomiting—Carmustine—melanoma	0.000279	0.00106	CcSEcCtD
Eletriptan—Nausea—Dactinomycin—melanoma	0.000279	0.00105	CcSEcCtD
Eletriptan—Shock—Docetaxel—melanoma	0.000278	0.00105	CcSEcCtD
Eletriptan—Rash—Carmustine—melanoma	0.000277	0.00105	CcSEcCtD
Eletriptan—Nervous system disorder—Docetaxel—melanoma	0.000277	0.00105	CcSEcCtD
Eletriptan—Dermatitis—Carmustine—melanoma	0.000277	0.00105	CcSEcCtD
Eletriptan—Tachycardia—Docetaxel—melanoma	0.000275	0.00104	CcSEcCtD
Eletriptan—Headache—Carmustine—melanoma	0.000275	0.00104	CcSEcCtD
Eletriptan—Skin disorder—Docetaxel—melanoma	0.000274	0.00104	CcSEcCtD
Eletriptan—Vomiting—Temozolomide—melanoma	0.00027	0.00102	CcSEcCtD
Eletriptan—Anorexia—Docetaxel—melanoma	0.000269	0.00102	CcSEcCtD
Eletriptan—Rash—Temozolomide—melanoma	0.000267	0.00101	CcSEcCtD
Eletriptan—Dermatitis—Temozolomide—melanoma	0.000267	0.00101	CcSEcCtD
Eletriptan—Headache—Temozolomide—melanoma	0.000266	0.001	CcSEcCtD
Eletriptan—Hypotension—Docetaxel—melanoma	0.000264	0.000997	CcSEcCtD
Eletriptan—Nausea—Carmustine—melanoma	0.000261	0.000986	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Docetaxel—melanoma	0.000257	0.000972	CcSEcCtD
Eletriptan—Insomnia—Docetaxel—melanoma	0.000255	0.000965	CcSEcCtD
Eletriptan—Paraesthesia—Docetaxel—melanoma	0.000253	0.000958	CcSEcCtD
Eletriptan—Nausea—Temozolomide—melanoma	0.000252	0.000953	CcSEcCtD
Eletriptan—Dyspnoea—Docetaxel—melanoma	0.000252	0.000951	CcSEcCtD
Eletriptan—Somnolence—Docetaxel—melanoma	0.000251	0.000948	CcSEcCtD
Eletriptan—ABCB1—head—melanoma	0.000249	0.00494	CbGeAlD
Eletriptan—Dyspepsia—Docetaxel—melanoma	0.000248	0.000939	CcSEcCtD
Eletriptan—Decreased appetite—Docetaxel—melanoma	0.000245	0.000927	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Docetaxel—melanoma	0.000244	0.000921	CcSEcCtD
Eletriptan—Fatigue—Docetaxel—melanoma	0.000243	0.00092	CcSEcCtD
Eletriptan—Pain—Docetaxel—melanoma	0.000241	0.000912	CcSEcCtD
Eletriptan—Constipation—Docetaxel—melanoma	0.000241	0.000912	CcSEcCtD
Eletriptan—Feeling abnormal—Docetaxel—melanoma	0.000232	0.000879	CcSEcCtD
Eletriptan—Gastrointestinal pain—Docetaxel—melanoma	0.000231	0.000872	CcSEcCtD
Eletriptan—Abdominal pain—Docetaxel—melanoma	0.000223	0.000843	CcSEcCtD
Eletriptan—Body temperature increased—Docetaxel—melanoma	0.000223	0.000843	CcSEcCtD
Eletriptan—Hypersensitivity—Docetaxel—melanoma	0.000208	0.000786	CcSEcCtD
Eletriptan—Asthenia—Docetaxel—melanoma	0.000202	0.000765	CcSEcCtD
Eletriptan—Pruritus—Docetaxel—melanoma	0.0002	0.000755	CcSEcCtD
Eletriptan—Diarrhoea—Docetaxel—melanoma	0.000193	0.00073	CcSEcCtD
Eletriptan—Dizziness—Docetaxel—melanoma	0.000187	0.000705	CcSEcCtD
Eletriptan—Vomiting—Docetaxel—melanoma	0.000179	0.000678	CcSEcCtD
Eletriptan—Rash—Docetaxel—melanoma	0.000178	0.000673	CcSEcCtD
Eletriptan—Dermatitis—Docetaxel—melanoma	0.000178	0.000672	CcSEcCtD
Eletriptan—Headache—Docetaxel—melanoma	0.000177	0.000668	CcSEcCtD
Eletriptan—ABCB1—lymph node—melanoma	0.000174	0.00346	CbGeAlD
Eletriptan—Nausea—Docetaxel—melanoma	0.000168	0.000634	CcSEcCtD
Eletriptan—HTR1A—Signaling Pathways—KIT—melanoma	1.13e-05	6.34e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CG—melanoma	1.13e-05	6.34e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—NRAS—melanoma	1.13e-05	6.34e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CXCL8—melanoma	1.13e-05	6.3e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.12e-05	6.27e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGF—melanoma	1.12e-05	6.26e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—HRAS—melanoma	1.12e-05	6.26e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CXCL8—melanoma	1.12e-05	6.26e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—HRAS—melanoma	1.11e-05	6.22e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—PIK3CA—melanoma	1.11e-05	6.21e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—PIK3CA—melanoma	1.11e-05	6.18e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MDM2—melanoma	1.1e-05	6.15e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CDKN1B—melanoma	1.1e-05	6.15e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CXCL8—melanoma	1.1e-05	6.13e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CDKN1B—melanoma	1.09e-05	6.11e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—HRAS—melanoma	1.09e-05	6.09e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CD—melanoma	1.09e-05	6.08e-05	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—AKT1—melanoma	1.09e-05	6.08e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—MAPK3—melanoma	1.09e-05	6.07e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—ERBB2—melanoma	1.09e-05	6.07e-05	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—AKT1—melanoma	1.08e-05	6.04e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CASP3—melanoma	1.08e-05	6.03e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—VCAN—melanoma	1.08e-05	6.02e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL2—melanoma	1.08e-05	6.02e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—ALB—melanoma	1.07e-05	6.01e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TP53—melanoma	1.07e-05	6e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CB—melanoma	1.07e-05	5.99e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—IL6—melanoma	1.07e-05	5.99e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CASP3—melanoma	1.07e-05	5.99e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1B—melanoma	1.07e-05	5.98e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL2—melanoma	1.07e-05	5.98e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—BRAF—melanoma	1.07e-05	5.96e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—IL6—melanoma	1.06e-05	5.95e-05	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—AKT1—melanoma	1.06e-05	5.92e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCND1—melanoma	1.05e-05	5.87e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CASP3—melanoma	1.05e-05	5.86e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ABCB1—melanoma	1.05e-05	5.85e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL2—melanoma	1.05e-05	5.85e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—PIK3CA—melanoma	1.05e-05	5.85e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCND1—melanoma	1.04e-05	5.83e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—IL6—melanoma	1.04e-05	5.82e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CTNNB1—melanoma	1.04e-05	5.81e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IGF1—melanoma	1.04e-05	5.8e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—MAPK1—melanoma	1.03e-05	5.77e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—EGFR—melanoma	1.03e-05	5.77e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CTNNB1—melanoma	1.03e-05	5.77e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCL8—melanoma	1.03e-05	5.75e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—HRAS—melanoma	1.03e-05	5.74e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.02e-05	5.72e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—HRAS—melanoma	1.02e-05	5.72e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCND1—melanoma	1.02e-05	5.71e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MMP9—melanoma	1.02e-05	5.7e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CDKN1A—melanoma	1.02e-05	5.68e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—melanoma	1.01e-05	5.66e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PTEN—melanoma	1.01e-05	5.66e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MMP9—melanoma	1.01e-05	5.66e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CTNNB1—melanoma	1.01e-05	5.65e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CDKN1A—melanoma	1.01e-05	5.64e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NFKB1—melanoma	1.01e-05	5.64e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PTEN—melanoma	1.01e-05	5.63e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1B—melanoma	1.01e-05	5.62e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CB—melanoma	1e-05	5.61e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAP2K1—melanoma	1e-05	5.61e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NFKB1—melanoma	1e-05	5.6e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CD—melanoma	9.97e-06	5.57e-05	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—AKT1—melanoma	9.95e-06	5.56e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTGS2—melanoma	9.94e-06	5.56e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MMP9—melanoma	9.91e-06	5.54e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—AKT1—melanoma	9.88e-06	5.52e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1A—melanoma	9.88e-06	5.52e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—PIK3CA—melanoma	9.87e-06	5.52e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PTEN—melanoma	9.86e-06	5.51e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CASP3—melanoma	9.85e-06	5.51e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL2—melanoma	9.84e-06	5.5e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL6—melanoma	9.83e-06	5.5e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—AKT1—melanoma	9.82e-06	5.49e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NFKB1—melanoma	9.81e-06	5.48e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL6—melanoma	9.79e-06	5.47e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—KRAS—melanoma	9.76e-06	5.45e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—HRAS—melanoma	9.69e-06	5.42e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PRKCA—melanoma	9.64e-06	5.39e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ABCB1—melanoma	9.64e-06	5.38e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—AKT1—melanoma	9.62e-06	5.37e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCND1—melanoma	9.59e-06	5.36e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ERCC2—melanoma	9.56e-06	5.34e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ABCB1—melanoma	9.55e-06	5.34e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—FGF2—melanoma	9.54e-06	5.33e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CTNNB1—melanoma	9.5e-06	5.31e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CB—melanoma	9.49e-06	5.3e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PRKCA—melanoma	9.41e-06	5.26e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTGS2—melanoma	9.4e-06	5.26e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ERCC2—melanoma	9.33e-06	5.22e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MMP9—melanoma	9.31e-06	5.2e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1A—melanoma	9.28e-06	5.19e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL6—melanoma	9.28e-06	5.18e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PTEN—melanoma	9.26e-06	5.17e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NFKB1—melanoma	9.21e-06	5.15e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—VEGFA—melanoma	9.15e-06	5.11e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—VEGFA—melanoma	9.09e-06	5.08e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP17A1—melanoma	9.09e-06	5.08e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—AKT1—melanoma	9.07e-06	5.07e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—STAT3—melanoma	9.06e-06	5.06e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NRAS—melanoma	9.04e-06	5.05e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—AKT1—melanoma	9.03e-06	5.05e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—STAT3—melanoma	9e-06	5.03e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NRAS—melanoma	8.98e-06	5.02e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—PIK3CA—melanoma	8.97e-06	5.01e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MDM2—melanoma	8.93e-06	4.99e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—VEGFA—melanoma	8.9e-06	4.98e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PRKCA—melanoma	8.87e-06	4.96e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—STAT3—melanoma	8.81e-06	4.93e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ERBB2—melanoma	8.8e-06	4.92e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ERCC2—melanoma	8.79e-06	4.91e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NRAS—melanoma	8.79e-06	4.91e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PRKCA—melanoma	8.79e-06	4.91e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ERCC2—melanoma	8.72e-06	4.87e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CB—melanoma	8.69e-06	4.86e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTEN—melanoma	8.67e-06	4.85e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK3—melanoma	8.66e-06	4.84e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK3—melanoma	8.6e-06	4.81e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GNA11—melanoma	8.58e-06	4.8e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—AKT1—melanoma	8.56e-06	4.78e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK3—melanoma	8.42e-06	4.71e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MYC—melanoma	8.42e-06	4.71e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—FASN—melanoma	8.4e-06	4.69e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MYC—melanoma	8.37e-06	4.67e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—VEGFA—melanoma	8.36e-06	4.67e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL8—melanoma	8.35e-06	4.67e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—HRAS—melanoma	8.3e-06	4.64e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—STAT3—melanoma	8.28e-06	4.63e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—SLC5A5—melanoma	8.26e-06	4.62e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NRAS—melanoma	8.26e-06	4.62e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK1—melanoma	8.24e-06	4.6e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EGFR—melanoma	8.24e-06	4.6e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTEN—melanoma	8.2e-06	4.58e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MYC—melanoma	8.19e-06	4.58e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK1—melanoma	8.18e-06	4.57e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EGFR—melanoma	8.18e-06	4.57e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1B—melanoma	8.15e-06	4.56e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—AKT1—melanoma	8.07e-06	4.51e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK1—melanoma	8.01e-06	4.48e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EGFR—melanoma	8.01e-06	4.48e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CASP3—melanoma	7.99e-06	4.47e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL2—melanoma	7.98e-06	4.46e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GNAQ—melanoma	7.98e-06	4.46e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CD44—melanoma	7.98e-06	4.46e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL6—melanoma	7.94e-06	4.44e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.92e-06	4.43e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK3—melanoma	7.91e-06	4.42e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—KRAS—melanoma	7.78e-06	4.35e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCND1—melanoma	7.78e-06	4.35e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—KRAS—melanoma	7.73e-06	4.32e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CTNNB1—melanoma	7.7e-06	4.31e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MYC—melanoma	7.69e-06	4.3e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP1B1—melanoma	7.65e-06	4.28e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—KRAS—melanoma	7.57e-06	4.23e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MMP9—melanoma	7.55e-06	4.22e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CG—melanoma	7.55e-06	4.22e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK1—melanoma	7.53e-06	4.21e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EGFR—melanoma	7.53e-06	4.21e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1A—melanoma	7.53e-06	4.21e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PTEN—melanoma	7.51e-06	4.2e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NFKB1—melanoma	7.47e-06	4.18e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CG—melanoma	7.37e-06	4.12e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—AKT1—melanoma	7.32e-06	4.09e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PPARG—melanoma	7.29e-06	4.07e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.22e-06	4.04e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CA—melanoma	7.15e-06	3.99e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PPARG—melanoma	7.11e-06	3.98e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—KRAS—melanoma	7.11e-06	3.97e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CA—melanoma	7.1e-06	3.97e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CA—melanoma	6.95e-06	3.89e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CG—melanoma	6.95e-06	3.88e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—melanoma	6.91e-06	3.86e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CG—melanoma	6.89e-06	3.85e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—melanoma	6.87e-06	3.84e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—VEGFA—melanoma	6.78e-06	3.79e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—melanoma	6.73e-06	3.76e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—STAT3—melanoma	6.71e-06	3.75e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PPARG—melanoma	6.7e-06	3.75e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NRAS—melanoma	6.7e-06	3.74e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PPARG—melanoma	6.65e-06	3.71e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CD—melanoma	6.64e-06	3.71e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—HRAS—melanoma	6.61e-06	3.7e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—HRAS—melanoma	6.57e-06	3.67e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ALB—melanoma	6.55e-06	3.66e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CA—melanoma	6.53e-06	3.65e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CD—melanoma	6.48e-06	3.62e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—HRAS—melanoma	6.43e-06	3.6e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK3—melanoma	6.42e-06	3.59e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ALB—melanoma	6.4e-06	3.57e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL6—melanoma	6.33e-06	3.54e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—melanoma	6.32e-06	3.53e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCB1—melanoma	6.3e-06	3.52e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL6—melanoma	6.29e-06	3.51e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MYC—melanoma	6.24e-06	3.49e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL6—melanoma	6.16e-06	3.44e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CA—melanoma	6.12e-06	3.42e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CD—melanoma	6.11e-06	3.41e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK1—melanoma	6.1e-06	3.41e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGFR—melanoma	6.1e-06	3.41e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CD—melanoma	6.05e-06	3.38e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—HRAS—melanoma	6.04e-06	3.38e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ALB—melanoma	6.03e-06	3.37e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ALB—melanoma	5.98e-06	3.34e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—AKT1—melanoma	5.84e-06	3.26e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—AKT1—melanoma	5.8e-06	3.24e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PRKCA—melanoma	5.8e-06	3.24e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CB—melanoma	5.79e-06	3.23e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CA—melanoma	5.79e-06	3.23e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL6—melanoma	5.78e-06	3.23e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KRAS—melanoma	5.77e-06	3.22e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ERCC2—melanoma	5.75e-06	3.21e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTGS2—melanoma	5.73e-06	3.2e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—AKT1—melanoma	5.68e-06	3.17e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CB—melanoma	5.65e-06	3.16e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTGS2—melanoma	5.6e-06	3.13e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—AKT1—melanoma	5.34e-06	2.98e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CB—melanoma	5.32e-06	2.97e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CA—melanoma	5.3e-06	2.96e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CB—melanoma	5.28e-06	2.95e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTGS2—melanoma	5.27e-06	2.95e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTGS2—melanoma	5.23e-06	2.92e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—melanoma	5.12e-06	2.86e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTEN—melanoma	5e-06	2.79e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—AKT1—melanoma	5e-06	2.79e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HRAS—melanoma	4.9e-06	2.74e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTEN—melanoma	4.88e-06	2.73e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—AKT1—melanoma	4.73e-06	2.64e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6—melanoma	4.69e-06	2.62e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTEN—melanoma	4.6e-06	2.57e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTEN—melanoma	4.56e-06	2.55e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CG—melanoma	4.54e-06	2.54e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPARG—melanoma	4.38e-06	2.45e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—AKT1—melanoma	4.33e-06	2.42e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CD—melanoma	3.99e-06	2.23e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALB—melanoma	3.94e-06	2.2e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CA—melanoma	3.53e-06	1.97e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CB—melanoma	3.48e-06	1.94e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTGS2—melanoma	3.45e-06	1.93e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CA—melanoma	3.44e-06	1.92e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CA—melanoma	3.24e-06	1.81e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CA—melanoma	3.22e-06	1.8e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTEN—melanoma	3.01e-06	1.68e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AKT1—melanoma	2.88e-06	1.61e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AKT1—melanoma	2.81e-06	1.57e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AKT1—melanoma	2.65e-06	1.48e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AKT1—melanoma	2.63e-06	1.47e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CA—melanoma	2.12e-06	1.19e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AKT1—melanoma	1.73e-06	9.68e-06	CbGpPWpGaD
